Resistance of HR+/HER2+ breast cancer to endocrine therapy is heterogeneous and complex and may depend on the individual patient’s genetic background, the choice of endocrine therapy, and the type of resistance (Dixon 2014). Here, ERBB2 is linked to breast carcinoma.